Patents by Inventor James H. McLinden

James H. McLinden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of inducing a cross-reactive HIV-1 immune response by administering a composition comprising the GBV-C E2 protein
    Patent number: 10034936
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: July 31, 2018
    Assignees: The University of Iowa Research Foundation, The United States of America as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • GB virus C (hepatitis G virus) E2 glycoprotein as an immunomodulatory agent
    Patent number: 9611301
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving GBV-C E2 polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 4, 2017
    Assignees: The University of Iowa Research Foundation, The United States of America as Represented by The Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Nirjal Bhattarai, Jinhua Xiang, James H. McLinden
  • VIRAL PROTEINS AS IMMUNOMODULATORY AGENTS AND VACCINE COMPONENTS
    Publication number: 20160067331
    Abstract: The invention provides compositions and methods involving viral envelope polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation. In addition, modification of the viral sequences responsible for modulating immune response provides for improved vaccine formulations.
    Type: Application
    Filed: March 14, 2014
    Publication date: March 10, 2016
    Inventors: Jack T. STAPLETON, Nirjal BHATTARAI, Jinhua XIANG, James H. MCLINDEN
  • GB VIRUS C (HEPATITIS G VIRUS) E2 GLYCOPROTEIN AS AN IMMUNOMODULATORY AGENT
    Publication number: 20150071955
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving GBV-C E2 polypeptides and peptides for use in modulating immune responses, including inhibition inflammation related to pathogenic T-cell activation.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 12, 2015
    Applicant: THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Jack T. Stapleton, Nirjal Bhattarai, Jinhua Xiang, James H. McLinden
  • GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV
    Publication number: 20140348866
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Application
    Filed: August 15, 2014
    Publication date: November 27, 2014
    Applicants: THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT
    Inventors: Jack T. STAPLETON, Jinhua XIANG, Donna KLINZMAN, James H. McLINDEN
  • Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies
    Patent number: 8858946
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: October 14, 2014
    Assignees: The University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • GB VIRUS C (HEPATITIS G VIRUS) FOR THE TREATMENT OF HIV
    Publication number: 20090010932
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Application
    Filed: July 24, 2008
    Publication date: January 8, 2009
    Inventors: JACK T. STAPLETON, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • Recombianant Hepatitis a virus
    Patent number: 5294548
    Abstract: The present invention is directed to genetically engineered expression systems which encode a recombinant Hepatitis A virus (HAV) proteins capable of forming capsid particles. By way of example baculovirus vectors were utilized in order to express recombinant HAV proteins. The recombinant baculoviruses of the invention are formed by replacing regions of the polyhedrin structural gene coding sequences with HAV DNA by recombinant DNA techniques. Additionally, the polyhedrin transcriptional initiation site is altered in these recombinant baculoviruses such that only HAV proteins and not polyhedrin protein sequences are expressed from the polyhedrin promoter. The recombinant HAV capsid particles produced in accordance with the present invention can be particularly useful as vaccines.
    Type: Grant
    Filed: July 3, 1991
    Date of Patent: March 15, 1994
    Assignees: American Biogenetic Sciences, Inc, University of Iowa Research Foundation
    Inventors: James H. McLinden, Elliot D. Rosen, Patricia L. Winokur, Jack T. Stapleton